Biotech Innovation

REGENXBIO: 60% of Sura-Vec Patients Show DRSS Gains at 3 Years

Rockville, Md. – September 25, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) reported that 60% of Dose Level 3 participants with three-year follow-up data in its Phase II ALTITUDE study achieved a greater-than-2-step improvement on the Diabetic Retinopathy Severity Scale (DRSS) after a single in-office treatment with investigational gene therapy sura-vec, with no vision-threatening events recorded among responders.

Three-year data confirm durable DRSS improvement without repeat injections

In long-term follow-up as of September 25, 2026, six of ten Dose Level 3 participants with non-proliferative diabetic retinopathy (NPDR) who reached the three-year visit sustained a greater-than-2-step DRSS improvement without additional diabetic retinopathy treatment. The suprachoroidal delivery used Dose Level 3 (1.0x10^12 GC/eye) combined with short-course prophylactic topical steroids.

Sanyou Bio, NovoCodex Partner to Co-Develop Dual-Payload ADCs

Shanghai – September 25, 2026 -- Sanyou Biopharmaceuticals Co., Ltd. and NovoCodex Biopharmaceuticals Co., Ltd. have signed a strategic collaboration agreement to jointly develop next-generation antibody-drug conjugates (ADCs), combining Sanyou Bio's AI-driven antibody discovery platforms with NovoCodex's clinically validated site-specific conjugation technology.

NovoCodex brings a clinically validated conjugation platform to the partnership

NovoCodex's proprietary NovoCodeTM platform incorporates unnatural amino acids into antibodies to achieve defined, controllable conjugation sites, producing homogeneous ADC products rather than the heterogeneous mixtures typical of traditional random conjugation. The technology has been validated in the pivotal Phase III trial of ARX788 and supported ARX305 in showing a favorable safety window and durable antitumor activity in advanced renal cancer patients with high CD70 expression.

Basecamp Research Raises $140M to Advance AI-Designed Cell Therapies

London and Boston – September 25, 2026 -- Basecamp Research has closed a $140 million oversubscribed Series C financing to train new EDEN foundation models and push a pipeline of AI-designed therapeutics toward clinical development.

S32 leads a syndicate spanning NVIDIA, Anthropic-adjacent backers and sovereign funds

The round was led by S32, with participation from NVIDIA, Menlo Ventures' Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures. Andy Conrad, General Partner at S32 and former CEO of Google's Verily, joins Basecamp's Board of Directors.

Eterna Regeneratives Raises Seed Funding for Keratin Enamel Repair Tech

London – September 20, 2026 -- UK biotech spin-out Eterna Regeneratives has closed a seed funding round led by Hoxton Ventures and The Venture Collective to commercialize a keratin-based material that regrows tooth enamel, targeting the $43 billion global oral care market.

King's College London spin-out moves from lab to commercial pipeline

Co-founded in 2024 by Khaled Eissa and Dr Sherif Elsharkawy, Eterna emerged from research led by Elsharkawy and PhD student Dr Sara Gamea that drew coverage from the BBC, Washington Post and Newsweek after demonstrating keratin's capacity to regrow damaged enamel. The seed round funds the shift from proof-of-concept research to real-world product development, according to Elsharkawy, the company's Chief Scientific Officer.

Esperovax Wins USPTO Nod for In Vivo Yeast Protein Platform

Plymouth, Mich. – – September 17, 2026 -- Esperovax, Inc. has secured a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application No. 18/038,673, covering its engineered yeast platform for producing therapeutic proteins directly inside the body.

USPTO clears patent covering in vivo yeast-based protein expression

The allowed application, titled "Yeast-Based Expression of Therapeutic Proteins In Vivo," protects technology that uses engineered yeast administered to patients to manufacture biologic proteins within the body itself, rather than requiring external production and repeated dosing of purified biologics.

Anixa Biosciences CEO, Trial Patient to Discuss Breast Cancer Vaccine on Bloomberg TV

San Jose, Calif. – September 14, 2026 -- Anixa Biosciences, Inc. (NASDAQ: ANIX) confirmed that Bloomberg TV will air an interview with Chairman and CEO Dr. Amit Kumar and breast cancer vaccine trial patient Sherie Steinberg this Saturday, September 12, at 7:00 PM ET, reaching an estimated 73 million U.S. homes.

Bloomberg TV segment to spotlight breast cancer vaccine data and patient outcomes

The interview will air on the RedChip Small Stocks, Big Money show and is also available online. Dr. Kumar is expected to detail recent progress in Anixa's cancer vaccine development program, including a breast cancer vaccine designed for three applications: treating existing disease, preventing recurrence, and reducing the risk of initial onset in high-risk patients.